Business Context and Reporting Period
Company: Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines.
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Reporting Period: March 2026.
Key Event: The filing serves to incorporate by reference a press release dated March 19, 2026, announcing the convening of the Company's Annual General Meeting (AGM).
Financial Metrics
This filing is a procedural notice regarding a corporate governance event and does not contain financial statements or performance data.
- Revenue: Not provided in this filing.
- Profit/Loss: Not provided in this filing.
- Cash Flow: Not provided in this filing.
- Debt and Liquidity: Not provided in this filing.
Material Changes
No material changes to financial performance or operational status are reported in this document. The filing solely communicates the scheduling of the Annual General Meeting.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the AGM but does not include specific management commentary on business outlook, guidance, or strategic updates within the text of the Form 6-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing.
Key Facts for Investor Verification
- Verify the date, time, and location of the Annual General Meeting by reviewing the full text of the press release (Exhibit 99.1) referenced in this filing.
- Confirm the specific agenda items and proposals to be voted on at the AGM, as these are not listed in the Form 6-K summary.
- Note that this filing does not update the Company's financial position; investors should refer to the most recent Form 20-F or quarterly reports for financial data.